- Home
- IHT vs HIND Comparison
IHT vs HIND Comparison
Compare IHT & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | IHT | HIND |
|---|---|---|
| Founded | 1971 | 2017 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Investment Bankers/Brokers/Service | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 15.2M |
| IPO Year | 1995 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IHT | HIND |
|---|---|---|
| Price | $1.12 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | ★ 37.1K | 15.8K |
| Earning Date | 09-16-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,600,000.00 | $319,714.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $82.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.33 | ★ 24.43 |
| 52 Week Low | $0.95 | $1.75 |
| 52 Week High | $1.90 | $6.56 |
Technical Indicators
Market Signals| Indicator | IHT | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 24.18 | 49.51 |
| Support Level | $1.01 | $2.00 |
| Resistance Level | $1.12 | $2.33 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 20.35 | 41.67 |
Price Performance
Historical ComparisonAbout IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.